A Breakthrough Blood Test for Prostate Cancer To be Premiered by 5Q Spectra at Davos of Healthcare™

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- The Davos of Healthcare™ Summit, on September 14 in New York City, will proudly host the global launch of 5Q Spectra's Prostate Dx™, known as the "PSB" Blood Test (Prostate Specific Biomarker test), marking a medical breakthrough and the significant new chapter in the company's 15-year effort to advance blood-based cancer diagnostics.

The Summit: Where "medical research, AI and biotech are racing to end disease," brings together world leading hospitals, scientists, biotechnology companies, healthcare executives, investment and innovators focused on translating breakthrough science into real-world medicine.

5Q Spectra's biotechnology is a fundamental medical breakthrough in prostate cancer diagnosis: when an elevated "PSA" level signals the need for further investigation, but cannot and does not establish whether clinically significant cancer is actually present.

"Davos of Healthcare brings extraordinary medical science and clinical leadership to a global healthcare stage," according to Ransel N. Potter, Founder. "And 5Q Spectra's new 'PSB' blood test is just that; addressing a critical diagnostic gap in today's medicine — helping men and patients beyond the uncertainty of a frightening elevated 'PSA' toward precise biological information that can guide the next step in care."

For decades, elevated PSA levels have been the principal warning signal for men's prostate cancer. However, PSA levels also rise because of benign prostate enlargement, inflammation, infection and multiple other non-cancerous conditions. As a result, many men undergo repeated testing, imaging, surveillance or a painful unnecessary invasive surgical biopsy, most-often without prostate cancer found.

5Q Spectra; a global leader in clinical liquid biopsy, has spent 15 years and more than C$85 million invested in the underlying science and R&D seeking to address this medical gap for men between an elevated "PSA" and surgical biopsy. The company reports their "PSB" blood test establishes an extraordinary reliability of an 0.86 AUC diagnostic discrimination, increasing to approximately 0.92 when combined with imaging and its clinical-intelligence AI platform. At a selected high-sensitivity threshold, the company reports approximately 95% sensitivity and the potential to eliminate up to 44% of unnecessary surgical biopsies.

"An elevated PSA certainly tells us when we should look further, but it was never designed to tell us whether prostate cancer is actually there," said Steve de Jaray, Co-Founder, Chairman and CEO of 5Q Spectra. "Our ambition has been quite simple: when a PSA level raises the alarm, our easy PSB blood test provides physicians and patients with better cancer-specific biological information about what that alarm means."

The Summit will feature a 5Q expert medical panel on early prostate cancer detection, including global leaders in urology, radiation oncology and prostate surgery, alongside the perspective of a prostate cancer survivor. The discussion will examine the medical science, clinical evidence and emerging role of the new breakthrough PSB blood test for prostate cancer in today's contemporary urologic oncology practice.

About C³ Davos of Healthcare™

C³ convenes healthcare, scientific, business and international leaders around cross-border collaboration, public-private partnerships and commercialization of innovation.

About 5Q Spectra Corp.

5Q Spectra develops blood-based molecular diagnostic technologies designed as clinical tools to support earlier and more actionable recognition of cancer. Its flagship Prostate Dx™ / PSB test in use by urologists following an elevated PSA and is currently available as a Laboratory Developed Test (LDT) through CLIA-certified laboratories.

Contact: Steve de Jaray Web: 5QSpectra.com, Email: [email protected], Call: 1.689.888.8889

SOURCE 5Q Spectra